Screener
BBH vs IHE
VanEck Biotech ETF vs iShares U.S. Pharmaceuticals ETF
Key differences
- Over the last 3 years, IHE has delivered higher annualized returns.
- IHE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| BBH | IHE | |
|---|---|---|
| Annual cost (TER) | 0.35% | 0.38% |
| Fund size (AUM) | $365M | $946M |
| Since | 2011 | 2006 |
| Dividend yield | 0.52% | 1.70% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +26.8% | +46.2% |
| CAGR 3Y | +5.9% | +18.0% |
| CAGR 5Y | +1.2% | +10.1% |
| Sharpe 3Y | 0.21 | 0.87 |
| Volatility 1Y | 18.82% | 16.91% |
| Max drawdown | -39.86% | -29.59% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to BBH and IHE
Explore further